2023
Patient Preferences for Postmastectomy Breast Reconstruction
Shammas R, Hung A, Mullikin A, Sergesketter A, Lee C, Reed S, Fish L, Greenup R, Hollenbeck S. Patient Preferences for Postmastectomy Breast Reconstruction. JAMA Surgery 2023, 158: 1285-1292. PMID: 37755818, PMCID: PMC10535024, DOI: 10.1001/jamasurg.2023.4432.Peer-Reviewed Original ResearchConceptsRisk of complicationsBreast reconstructionAbdominal morbidityFlap reconstructionBreast cancerGenetic predispositionPatient-physician discussionsImplant-based reconstructionPostmastectomy breast reconstructionCross-sectional studyChance of complicationsPatient-centered careAdditional operationsHigher educational levelMajor complicationsPreoperative counselingPatient preferencesFlap appearanceTreatment preferencesImplant reconstructionMAIN OUTCOMENew diagnosisPatient valuesComplicationsMean increaseRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchMeSH KeywordsAdultBreast NeoplasmsCohort StudiesColorectal NeoplasmsHumansMaleMiddle AgedProstateProstatic NeoplasmsSurvivorsConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseAncillary Treatment Referrals and Visits After Breast Cancer Surgery in a Sociodemographically Diverse Population
Chan V, Heller D, Berger E, Capozza S, Greenup R, Sanft T. Ancillary Treatment Referrals and Visits After Breast Cancer Surgery in a Sociodemographically Diverse Population. Annals Of Surgical Oncology 2023, 30: 5637-5648. PMID: 37266804, DOI: 10.1245/s10434-023-13431-5.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleHealth Services AccessibilityHumansInsurance, HealthQuality of LifeReferral and ConsultationConceptsBreast cancer surgeryHealth care accessCancer surgeryMultivariable analysisAncillary treatmentHigher median household incomeHispanic ethnicityCare accessYale New Haven Health SystemBreast cancer surgical patientsPoor health care accessMedian household incomeEnd pointMultivariable logistic regression analysisHealth systemHigh school degreeCancer surgical patientsPrimary end pointLogistic regression analysisUrban cancer centerPostoperative referralPostoperative morbidityAdjunctive therapyProvider referralSurgical patientsMultidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer
Wheeler S, Spencer J, Manning M, Samuel C, Reeder‐Hayes K, Greenup R, Spees L, Rosenstein D. Multidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer. Cancer Medicine 2023, 12: 11930-11940. PMID: 37148550, PMCID: PMC10242847, DOI: 10.1002/cam4.5885.Peer-Reviewed Original ResearchModifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives
Fayanju O, Greenup R, Zafar S, Hyslop T, Hwang E, Fish L. Modifiable Barriers and Facilitators for Breast Cancer Care: A Thematic Analysis of Patient and Provider Perspectives. Journal Of Surgical Research 2023, 284: 269-279. PMID: 36610386, PMCID: PMC10020986, DOI: 10.1016/j.jss.2022.11.074.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCommunicationFemaleHumansMaleMiddle AgedQualitative ResearchReferral and ConsultationConceptsBreast cancer treatmentBreast cancerModifiable barriersCancer treatmentProvider perspectivesSurgical oncology careBreast cancer careAdvanced practice providersSingle health systemModifiable contributorOncologic careModifiable factorsOncology careCancer careTreatment receiptPatients' perceptionsStage 0Practice providersCare receiptPatientsExemplar quotesThematic analysisSuboptimal communicationHealth systemTreatment costs
2022
Genetic testing in privately insured women with surgically treated breast cancer
Dinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer. Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.Peer-Reviewed Original ResearchConceptsBreast cancerGenetic testingRoutine breast cancer careBRCA1/BRCA2 genetic testingHormone receptor statusBreast cancer careInvasive breast cancerBRCA2 genetic testingReceptor statusWomen 50Cancer careAge 45Family historyOlder womenInsurer databaseYoung womenCancerWomenCoverage policiesUnclear implicationsPatientsSurgeryPurposeRatesYearsPrevalence
2020
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Spring L, Fell G, Arfe A, Sharma C, Greenup R, Reynolds K, Smith B, Alexander B, Moy B, Isakoff S, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clinical Cancer Research 2020, 26: 2838-2848. PMID: 32046998, PMCID: PMC7299787, DOI: 10.1158/1078-0432.ccr-19-3492.Peer-Reviewed Original ResearchConceptsPathologic complete responseEvent-free survivalBetter event-free survivalNeoadjuvant chemotherapyAdjuvant chemotherapyOverall survivalComplete responseBreast cancerImproved event-free survivalIndividual patient-level dataAdditional adjuvant therapySubsequent adjuvant chemotherapyBreast cancer recurrencePatient-level dataComprehensive Meta-AnalysisAdjuvant settingNeoadjuvant responseAdjuvant therapyMicrometastatic diseaseImproved survivalPrognostic significanceSystemic clearanceCancer recurrenceInclusion criteriaChemotherapy
2019
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton M, Williamson H, Westbrook K, Greenup R, Plichta J, Rosenberger L, Gupta A, Hyslop T, Hwang E, Fayanju O. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. Annals Of Surgical Oncology 2019, 26: 3166-3177. PMID: 31342392, PMCID: PMC6736696, DOI: 10.1245/s10434-019-07564-9.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyInvasive lobular carcinomaOverall survivalEndocrine therapyLobular carcinomaHormone receptor-positive groupNational Cancer Data BaseLower ratesPathologic complete responseKaplan-Meier curvesReceptor-positive groupCox proportional hazardsBackgroundNeoadjuvant chemotherapyCN1-3More comorbiditiesPostmastectomy radiationNeoadjuvant chemotherapyNeoadjuvant therapyComplete responseClinical trialsBreast cancerCT classificationSmall tumorsProportional hazardsGreater burden
2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regressionAxillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival
Tamirisa N, Thomas S, Fayanju O, Greenup R, Rosenberger L, Hyslop T, Hwang E, Plichta J. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Annals Of Surgical Oncology 2018, 25: 2890-2898. PMID: 29968029, PMCID: PMC6404232, DOI: 10.1245/s10434-018-6595-2.Peer-Reviewed Original ResearchConceptsBreast cancer patientsElderly breast cancer patientsCN0 breast cancerOverall survivalNodal surgeryCancer patientsAxillary surgeryElderly patientsTreatment decisionsBreast cancerCharlson-Deyo comorbidity scoreCN0 breast cancer patientsSurgical lymph node evaluationCox proportional hazards modelAdjuvant therapy decisionsAdjuvant therapy receiptAxillary nodal evaluationLymph node evaluationNational Cancer DatabaseYear of diagnosisWorse overall survivalEstrogen receptor statusLong-term outcomesSubsequent treatment decisionsProportional hazards modelThe Effect of Hospital Volume on Breast Cancer Mortality
Greenup R, Obeng-Gyasi S, Thomas S, Houck K, Lane W, Blitzblau R, Hyslop T, Hwang E. The Effect of Hospital Volume on Breast Cancer Mortality. Annals Of Surgery 2018, 267: 375-381. PMID: 27893532, PMCID: PMC5994238, DOI: 10.1097/sla.0000000000002095.Peer-Reviewed Original ResearchConceptsHigh-volume centersNational Cancer Data BaseHospital volumeVolume centersBreast cancerHazard ratioImproved survivalStage 0Case volumeMultivariable Cox proportional hazards modelsMultidisciplinary breast cancer treatmentMultivariable Cox proportional hazardsSurgeons National Cancer Data BaseCox proportional hazards modelAnnual hospital volumeLess common cancersUnilateral breast cancerBreast cancer mortalityBreast cancer patientsCubic spline analysisLog-rank testBreast cancer treatmentCox proportional hazardsProportional hazards modelHigher case volume
2017
The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients
Cho E, Shammas R, Glener A, Greenup R, Hwang E, Hollenbeck S. The Impact of Autologous Breast Reconstruction on Body Mass Index Patterns in Breast Cancer Patients. Plastic & Reconstructive Surgery 2017, 140: 1121-1131. PMID: 29176410, DOI: 10.1097/prs.0000000000003841.Peer-Reviewed Original ResearchConceptsBody mass index (BMI) changeAutologous breast reconstructionBody mass index increaseBreast cancer patientsBody mass index (BMI) patternsBreast reconstructionCancer patientsMultivariable regressionNormal baseline body mass indexBaseline body mass indexImmediate autologous breast reconstructionCLINICAL QUESTION/LEVELHigh-risk patientsPropensity-matched pairsBody mass indexRisk of recurrenceWeight management strategiesBaseline obesityAdjuvant therapyTotal patientsMass indexTherapeutic mastectomyMastectomy patientsAutologous reconstructionAuthors' institutionPathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatientsAssociation Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
Shammas R, Cho E, Glener A, Poveromo L, Mundy L, Greenup R, Blackwell K, Hollenbeck S. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. Journal Of The American College Of Surgeons 2017, 225: 731-739.e1. PMID: 28985927, DOI: 10.1016/j.jamcollsurg.2017.08.023.Peer-Reviewed Original ResearchConceptsPostoperative wound breakdownBreast reconstructionReconstructive complicationsWound breakdownReconstructive operationsPropensity score-matched pairsMastectomy skin flap necrosisDuke University Medical CenterAdministration of trastuzumabPrimary study outcomeSkin flap necrosisLarger tumor sizePost-mastectomy reconstructionBreast reconstruction outcomesOccurrence of hematomaUniversity Medical CenterPertuzumab therapyChemotherapy regimenNeoadjuvant chemotherapyOperative interventionFlap thrombosisTrastuzumab therapySurgical outcomesTumor sizeFlap necrosisCost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analysesBreast Cancer after Augmentation
Cho E, Shammas R, Phillips B, Greenup R, Hwang E, Hollenbeck S. Breast Cancer after Augmentation. Plastic & Reconstructive Surgery 2017, 139: 1240e-1249e. PMID: 28538550, DOI: 10.1097/prs.0000000000003342.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast ImplantationBreast ImplantsBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMammaplastyMastectomyMiddle AgedMultivariate AnalysisPostoperative ComplicationsReference ValuesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurgical FlapsTime FactorsTreatment OutcomeUnited StatesConceptsPrior augmentationBreast cancer stageBreast cancerSubglandular augmentationCancer stageImplant placementCLINICAL QUESTION/LEVELPreferred reconstructive methodAdvanced breast tumorsTwo-stage implant reconstructionInvasive breast cancerBreast cancer screeningBreast cancer diagnosisUndergoing mastectomySubpectoral implantsDuctal carcinomaTherapeutic mastectomyCancer screeningTreatment recommendationsImplant reconstructionSubpectoral augmentationAuthors' institutionBreast augmentationMastectomyBreast tumorsMiniature spectral imaging device for wide-field quantitative functional imaging of the morphological landscape of breast tumor margins
Nichols B, Llopis A, Palmer G, McCachren S, Senlik O, Miller D, Brooke M, Jokerst N, Geradts J, Greenup R, Ramanujam N. Miniature spectral imaging device for wide-field quantitative functional imaging of the morphological landscape of breast tumor margins. Journal Of Biomedical Optics 2017, 22: 026007-026007. PMID: 28241273, PMCID: PMC5321165, DOI: 10.1117/1.jbo.22.2.026007.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleHumansMastectomy, SegmentalMiniaturizationMonte Carlo MethodSpectrum AnalysisConceptsBreast tumor marginsDiffuse optical spectroscopyVisible spectral rangeSpectral imaging deviceDiffuse reflectance spectraOptical spectroscopySpectral rangeImaging arrayMorphological landscapeRaster scanningOptical surrogatesImaging devicesQuantitative functional imagingReflectance spectraImaging platformImaging probeMonte CarloCompressive sensingInverse modelContent ratioWavelengthProbeFunctional imagingSpectroscopySpectra
2016
The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment
Obeng-Gyasi S, Tolnitch L, Greenup R, Shelley Hwang E. The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. Annals Of Surgical Oncology 2016, 23: 3412-3417. PMID: 27411550, PMCID: PMC5994757, DOI: 10.1245/s10434-016-5311-3.Peer-Reviewed Original ResearchA mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley M, Cardona D, Lazarides A, Spasojevic I, Ferrer J, Cahill J, Lee C, Snuderl M, Blazer D, Hwang E, Greenup R, Mosca P, Mito J, Cuneo K, Larrier N, O'Reilly E, Riedel R, Eward W, Strasfeld D, Fukumura D, Jain R, Lee W, Griffith L, Bawendi M, Kirsch D, Brigman B. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine 2016, 8: 320ra4. PMID: 26738797, PMCID: PMC4794335, DOI: 10.1126/scitranslmed.aad0293.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasLocal recurrenceTumor bedClinical trialsIntravenous injectionPhase 1 clinical trialHuman phase 1 clinical trialCo-clinical studiesMicroscopic residual cancerPositive surgical marginsFuture clinical trialsCo-clinical trialsRates of reexcisionAdjuvant therapyResidual cancerSurgical marginsTreatment failureTissue sarcomasBreast cancerCommon causeIntraoperative detectionMouse modelPharmacokinetic profileSolid tumorsCancer
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomy